Form 4: Pasithea Therapeutics Director Boosts Stake

Pasithea Therapeutics Corp. Director Simon Dumesnil acquired 33,333 shares of common stock at $0.75 per share.

Summary

• Simon Dumesnil, a Director of Pasithea Therapeutics Corp. (KTTA), purchased 33,333 shares of common stock.
• The transaction occurred on November 28, 2025, at a price of $0.75 per share.
• Following this acquisition, Mr. Dumesnil directly beneficially owns a total of 35,833 shares of Pasithea Therapeutics Corp. common stock.
• The total value of the shares acquired in this transaction is $24,999.75.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director's direct purchase of company stock, indicating confidence in the company's valuation and future prospects. The transaction amount, while not massive, is a clear vote of confidence.

Positives

• A Director's direct purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition increases the Director's alignment with shareholder interests.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or that significant positive developments are anticipated. This can sometimes precede periods of positive stock performance.

Comparison to Industry Standards

• Insider buying activity is a common indicator tracked by investors across all industries. While the specific amount of shares purchased by Director Dumesnil is not exceptionally large, any direct purchase by a director is generally viewed more favorably than, for example, an exercise of options followed by a sale.
• Compared to other biotech or pharmaceutical companies, insider purchases can be particularly impactful as they often operate with long development cycles and high R&D costs, making management's confidence a crucial factor.

Related Party Transactions

• The acquisition of 33,333 shares of common stock by Simon Dumesnil, a Director of Pasithea Therapeutics Corp., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing investor confidence and demand for the stock.
• Employees might perceive this as a sign of stability and positive future outlook from leadership.

Key Dates

Recommendation

The direct purchase of common stock by a company director, Simon Dumesnil, signals strong insider confidence in Pasithea Therapeutics Corp.'s current valuation and future prospects. Such transactions often precede positive developments or reflect a belief that the stock is undervalued. While this single transaction doesn't provide a complete picture, it serves as a compelling signal for investors to consider initiating or increasing a position, warranting a 'buy' recommendation based on this insider activity.

Keywords

Pasithea Therapeutics, KTTA, Insider Trading, Form 4, Director Purchase, Stock Acquisition, Simon Dumesnil, Beneficial Ownership